An observational study in Bacterial Infections, sponsored by Shandong University. Recruiting at 1 site in China. Open to participants aged Up to 18 Years. Per ClinicalTrials.gov, last updated 2020-04-14.
Sponsored by Shandong University · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 32 studies in Bacterial Infections with a site in China — 10 open to participants now, 10 under way, none of them phase 3. Bacterial Infections · China.
Among the 32 studies in Bacterial Infections with a site in China, this one is the 10th largest by planned enrollment of the 16 observational ones that give a count, is one of 5 that started in 2019, is one of 16 observational ones, and was the 12th registered.
586 studies on the registry are indexed under Bacterial Infections; 84 are open to participants now.
Browse Bacterial Infections studies →10 of the 32 studies in Bacterial Infections with a site in China are open now. Recruiting first, the newest first:
Joincare Pharmaceutical Group Industry Co., Ltd · Sites in China
Ages 18–45 · Healthy volunteers
The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School · Sites in China
Ages 18+
Eye & ENT Hospital of Fudan University · Sites in China
Ages 18+
The University of Hong Kong · Sites in China
Ages 18–100 · Healthy volunteers
Qilu Hospital of Shandong University · Sites in China
Ages 14+ · Healthy volunteers
A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →
Of the 56 Bacterial Infections studies recruiting now, 38 (68%) set no upper age limit and 13 (23%) stop at 75 or younger; 18 take children under 18; 6 take healthy volunteers.
This study: Up to 18 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
32 studies; the count open now beside each. This study's row is marked.
First in 2006; this study’s year is marked. 5 started in 2019.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 500 is above the median of 196 across 186 observational studies indexed under Bacterial Infections.
Median enrollment 259 across the 16 interventional studies, 628 across the 16 observational. Of the 15 that completed or were terminated, 4 (27%) have results posted.
This tab as a report to print or save as PDF → With an account.
11 of 32 have an industry lead sponsor. The 10 most frequent:
Shandong University is the lead sponsor of 295 studies on the registry; 63 are open to participants now.
Shandong University has 1 study filed under Bacterial Infections — fewer than ten, so there is no comparison to draw.
1 of the studies in Bacterial Infections with a site in China that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07612163The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical SchoolClinical Efficacy and Population Pharmacokinetics of β-lactams in Cirrhotic Patients | 2026-12-31 |
Add it to your calendar (.ics) → With an account.
Among the 32 studies in Bacterial Infections with a site in China, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
In this study, the therapeutic drug monitoring of teicoplanin is carried out among children to obtain the drug concentration, clinical efficacy and safety data of children patients in different gender and age groups. Then we analyze the relationship between blood drug concentration and efficacy and safety, and provide recommendations for the treatment window of teicoplanin in Chinese children.
Children with gram-positive coccus infection
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Therapeutic drug monitoring of teicoplanin
Plasma drug concentration
To detect the plasma concentrations of teicoplanin at therapeutic drug monitoring (TDM).
Time frame: Through study completion, an average of 14 days
Plan to share: Undecided
No publications or documents are linked to this record.
Started Apr 2019 (actual). Primary completion is estimated for Nov 2025, 79 months after the start.
Of 74 non-industry observational studies under Bacterial Infections, half reached primary completion within 23 months of starting (the median), counting those still running; a quarter within 12 and three quarters within 44. This study's planned 79 months is above that.
Counting every sponsor, half of 81 studies reached it within 22 months; a quarter within 12 and three quarters within 38.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.